Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), The Procter ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

A U.S. appeals court ruled that Novartis can't prevent MSN Pharmaceuticals' proposed generic of heart drug Entresto.

Centiva Capital LP reduced its stake in Novartis AG (NYSE:NVS – Free Report) by 48.1% during the 3rd quarter, HoldingsChannel ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novartis (NVS – Research Report), with a price target of ...

Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...

In celebration of Breast Cancer Awareness Month, Novartis and Healthway Cancer Care Hospital hosted the "Celebrating Strength ...

Novartis (NVS) announced results from an updated analysis of the pivotal Phase 3 NATALEE trial of Kisqali that it says “underscore the extended ...

Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...